The Bellvitge Biomedical Research Institute in Barcelona hosted the second plenary meeting of the PARADISE project on April 10th and 11th. The PARADISE project (PersonAlisation of RelApse risk in autoimmune DISEase) brings together partners across Europe as part of the ERA PerMed Joint translational call for proposals (2022) for “Prevention in personalised Medicine”. The Catholic University of Croatia, Digit-HeaL, is one of the partners actively involved in project activities.

Anamaria Malešević, a member of Digit-HeaL, presented the work of the PPI group (Patient and Public Involvement) and the work of the Patient Advisory Group during the plenary meeting. Plans for upcoming activities were outlined, and patient representatives further enriched the meeting.

At the meeting in Barcelona, partners from KTH Royal Institute of Technology (Sweden), the University of Freiburg (Germany), Firalis S.A. (France), The European Institute for Innovation through Health Data I-HD (Belgium), and Vasculitis Ireland Awareness (Ireland) participated, led by the project coordinator Prof. Dr. Mark Little from the Trinity Translational Medicine Institute and the ADAPT Center at Trinity College Dublin.

For more information about the PARADISE project, visit the official website or social media platforms (X and LinkedIn).

PARADISE